Matches in Nanopublications for { ?s ?p "[They also argue that combining PI3K/AKT/mTOR inhibitors with BH3 mimetics warrants attention in AML, particularly in the setting of basal AKT activation and/or addiction.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 12 of
12
with 100 items per page.
- NP769382.RAmlicTDuLtKVO0n5wJR2mF5aC9XYmcS2qocSY-0SOgZE130_assertion description "[They also argue that combining PI3K/AKT/mTOR inhibitors with BH3 mimetics warrants attention in AML, particularly in the setting of basal AKT activation and/or addiction.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP769382.RAmlicTDuLtKVO0n5wJR2mF5aC9XYmcS2qocSY-0SOgZE130_provenance.
- assertion description "[They also argue that combining PI3K/AKT/mTOR inhibitors with BH3 mimetics warrants attention in AML, particularly in the setting of basal AKT activation and/or addiction.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[They also argue that combining PI3K/AKT/mTOR inhibitors with BH3 mimetics warrants attention in AML, particularly in the setting of basal AKT activation and/or addiction.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP938770.RAh0rtug37xXzqf6lqQavzbF2N16YZ5j6vAxkKJQj0Z_A130_assertion description "[They also argue that combining PI3K/AKT/mTOR inhibitors with BH3 mimetics warrants attention in AML, particularly in the setting of basal AKT activation and/or addiction.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP938770.RAh0rtug37xXzqf6lqQavzbF2N16YZ5j6vAxkKJQj0Z_A130_provenance.
- NP444040.RAWzETJDhgnJ-R60RPbKoS_MORtL4hn49dB-FqEEKuu6M130_assertion description "[They also argue that combining PI3K/AKT/mTOR inhibitors with BH3 mimetics warrants attention in AML, particularly in the setting of basal AKT activation and/or addiction.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP444040.RAWzETJDhgnJ-R60RPbKoS_MORtL4hn49dB-FqEEKuu6M130_provenance.
- NP918859.RAlukc0l0eKxKDkaa32CnS1XSsa1aPB2IC_27T6RWkzdM130_assertion description "[They also argue that combining PI3K/AKT/mTOR inhibitors with BH3 mimetics warrants attention in AML, particularly in the setting of basal AKT activation and/or addiction.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP918859.RAlukc0l0eKxKDkaa32CnS1XSsa1aPB2IC_27T6RWkzdM130_provenance.
- NP322945.RAPdiWq5AFfNLDbmG-R_-1I8nk7gtJOikQH8QmPmeQC_Q130_assertion description "[They also argue that combining PI3K/AKT/mTOR inhibitors with BH3 mimetics warrants attention in AML, particularly in the setting of basal AKT activation and/or addiction.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP322945.RAPdiWq5AFfNLDbmG-R_-1I8nk7gtJOikQH8QmPmeQC_Q130_provenance.
- NP569935.RA-s7C8hfB1qIbAZ_3-SNTU1xp6PBog2kJd5YyVol6_pE130_assertion description "[They also argue that combining PI3K/AKT/mTOR inhibitors with BH3 mimetics warrants attention in AML, particularly in the setting of basal AKT activation and/or addiction.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP569935.RA-s7C8hfB1qIbAZ_3-SNTU1xp6PBog2kJd5YyVol6_pE130_provenance.
- NP602083.RAEm4hn1BMg79uyhgUDR9wwnvUFRm96AgeQdloIAtaYCg130_assertion description "[They also argue that combining PI3K/AKT/mTOR inhibitors with BH3 mimetics warrants attention in AML, particularly in the setting of basal AKT activation and/or addiction.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP602083.RAEm4hn1BMg79uyhgUDR9wwnvUFRm96AgeQdloIAtaYCg130_provenance.
- NP1036454.RAZzu1TESFVpO-rp2K3SfisHgGYSY94bhfXObYt7CsfIY130_assertion description "[They also argue that combining PI3K/AKT/mTOR inhibitors with BH3 mimetics warrants attention in AML, particularly in the setting of basal AKT activation and/or addiction.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1036454.RAZzu1TESFVpO-rp2K3SfisHgGYSY94bhfXObYt7CsfIY130_provenance.
- NP232312.RAgIgYZISHmQ37uhiIocbHwGmr34zMy27cen7yq8o_G44130_assertion description "[They also argue that combining PI3K/AKT/mTOR inhibitors with BH3 mimetics warrants attention in AML, particularly in the setting of basal AKT activation and/or addiction.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP232312.RAgIgYZISHmQ37uhiIocbHwGmr34zMy27cen7yq8o_G44130_provenance.
- NP232065.RAC22UGbg7Np6CdTNe9H3oC6j5PDktr_pVtuNo7gK8ozg130_assertion description "[They also argue that combining PI3K/AKT/mTOR inhibitors with BH3 mimetics warrants attention in AML, particularly in the setting of basal AKT activation and/or addiction.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP232065.RAC22UGbg7Np6CdTNe9H3oC6j5PDktr_pVtuNo7gK8ozg130_provenance.